Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 4/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10494608 | 0.82 | ACHE (0.50) | CES1ACHEALDH1A1MLYCD | |
| SCHEMBL3721831 | 0.81 | KDM4E (0.47) | ACHEALDH1A1MLYCD | |
| SCHEMBL29399874 | 0.80 | MYC (0.58) | RXRBRXRAALDH1A1MYC | |
| SCHEMBL44342 | 0.80 | MYC (0.58) | RXRBRXRAALDH1A1MYC | |
| SCHEMBL20768563 | 0.80 | RXRB (0.48) | RXRBRXRAALDH1A1NR1H4MYC | |
| SCHEMBL19200565 | 0.79 | ACHE (0.47) | CES1ACHEMLYCD | |
| SCHEMBL23391014 | 0.79 | RXRB (0.49) | RXRBRXRACES1ALDH1A1NR1H4 | |
| Ammonia Solution, Strong SCHEMBL11880552 | 0.78 | MYC (0.56) | RXRBRXRAALDH1A1MYC | |
| Water SCHEMBL3832510 | 0.78 | MYC (0.56) | RXRBRXRAALDH1A1MYC | |
| Hydrochloric Acid SCHEMBL3169435 | 0.78 | MYC (0.56) | RXRBRXRAALDH1A1MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021105840-A1 | PROCESS FOR PURIFICATION OF FLURALANER | HIKAL LIMITED (IN) | 2021-06-03 | — | — | WO | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | RXRB 4815/4885RXRA 4821/4885CES1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.